PF 5208766Alternative Names: WAY-178357
Latest Information Update: 29 Sep 2010
At a glance
- Originator Pfizer
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Sep 2010 Discontinued - Phase-I for Cancer in USA (unspecified route)
- 27 Jan 2010 Phase-I clinical trials in Cancer in USA (unspecified route)